World Health Organization Raises Alert Over Acute Shortage of Obesity Jabs
Under 10% of individuals who could benefit from obesity jabs including Wegovy are able to get them, warns the WHO as it releases its first recommendations on the medications.
With over a billion people worldwide now classified as obese, it is urging broader and more equitable access to this class of drugs.
According to forecasts, more than two billion are projected to be living with obesity by 2030 if no action is taken.
"Our latest guidance recognises that obesity is a lifelong illness that can be managed with comprehensive and lifelong support," said the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and distribution challenges are major hurdles to broad availability to the injections that can assist patients in reducing considerable body mass, notes the organization.
Skinny Jab Shortage
Despite the current best projected outlook, the supply of GLP-1 therapies might only reach approximately 100 million people – under 10% of the global need, as stated by the WHO.
The advice urges nations and manufacturers to expand availability, via measures including voluntary licensing.
Exclusive production rights on the active ingredient – the main component of Novo Nordisk's Wegovy – is due to expire in a number of nations in 2026.
The Way Obesity Drugs Work
The injections replicate a natural hormone to slow digestion, reduce hunger and increase feelings of fullness so individuals consume fewer calories.
People commonly begin shedding pounds after several weeks of beginning the regular doses.
Studies points to patients may see weight return a year later of halting the drug, when their normal appetite resume.
Being above a healthy weight elevates your risk for contracting medical conditions, including diabetes, cardiovascular issues, brain attack, and specific malignancies.
Obesity affects individuals in every country and was associated with millions of fatalities worldwide in 2024, per the WHO.
